Outlook Therapeutics
CompanyUnited StatesFounded 2015
Outlook Therapeutics develops one asset, in phase 3 (ONS-5010 in age-related macular degeneration). Based in the United States, founded in 2015.
- 1
- Asset
- Furthest stage
- Phase 3
- Raised
- $140M
- 5
- Trials
- 0
- Signals
Pipeline
1Phase 3, age-related macular degeneration, neovascular age-related macular degeneration
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms1
- Trials5
- Funding rounds and grants5
- Deals14
- People8
- Signals3
- Similar companies6